• 1,400 Staff Worldwide
    Global reach with local knowledge in 50+ countries
  • Exceptional Repeat & Referral Business
    A no-nonsense CRO with proven reputation for high quality and on time delivery
  • 5% staff turnover company-wide
    Guaranteed continuity of study teams, loyalty and accountability
  • 95% of psi studies complete on time
    Saving you money and time to market
PSI is a leading full-service global Contract Research Organization whose key strength is predictable patient enrollment across multiple therapeutic areas.
PSI Video
PSI is known in the industry as a CRO focused on on-time project delivery. This is achieved through investing substantial effort and MD resources into performing quality feasibility assessments that provide an accurate predictor of study timelines.
Learn More About PSI

Week 29, 2014

  • PSI completed enrollment in a phase III study of a novel antibiotic in patients with complicated urinary tract infections (cUTI).
  • PSI completed enrollment in a phase II study of a novel biological agent in patients with gastric cancer.
  • PSI completed a phase I study of a novel influenza vaccine.
  • PSI completed a phase III study of a novel biological agent in patients with hemophilia.
  • PSI completed a phase III study of a novel biological agent in patients with advanced breast cancer.


Read More


ICAAC 2014
September 5-9, 2014
Visit the Site  
View More


“Successful completion of patient recruitment in just over 12 months is a credit to the clinical team which has worked tirelessly to execute this trial within the tight timeline and budget”
Chief Scientific Officer, Australia February 2013
“I’m always impressed with how PSI employees conduct themselves and I frequently hear them say …”that is not a problem” no matter how big or small the request may be.”
Director Clinical Operations US January 2013
"PSI team, we got [drug] approved in US! This would not have been possible without all your efforts and your help. I wanted to thank all of you for this!”
Clinical Project Manager Austria June 2013
Read More



Zug, Switzerland, July 22, 2014 – PSI CRO, a full-service contract research organization, announced today the launch of a new global study in Polycythemia vera in collaboration with AOP Orphan. PSI is setting up this 100-patient open-label, multicenter study at 45 sites across 13 countries globally.
The new project is a result … Read More »

Read More


  • This field is for validation purposes and should be left unchanged.